en · de · es · pt
epitalon-notes.peptides7501.com › Wiki › Structure, Naming And Discovery — Quick Reference

Structure, Naming And Discovery — Quick Reference

By Editorial Desk · published 2025-08-05 · last reviewed 2025-09-15 · Wiki

tetrapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-09-15. Numbers and descriptions here follow the published literature rather than marketing material.

Structure, Naming and Discovery

The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.

Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.

Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.

Analytical Verification and Storage

No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.

Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.

The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.

Epitalon at a glance

PropertyValueNotes
Molecular formulaC14H22N4O9Derived from the four constituent residues
Molecular massAbout 390.35 DaMonoisotopic value, confirmed by mass spectrometry
Residue sequenceAla-Glu-Asp-GlyRead from the N-terminus to the C-terminus
Common synonymsEpithalon; AEDGBoth forms appear in reference catalogues
Net charge near neutral pHNegativeTwo acidic side chains give a low isoelectric point

Background and Proposed Mechanism

The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.

Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.

Related pages on this site

Analytical Characterization and Stability

Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.

Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.

Epitalon Background and Discovery

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.

Supporting material

=== Criminal justice === Kennedy opposed the First Step Act, a bipartisan criminal justice reform bill. The bill passed 87–12 on December 18, 2018. Kennedy said the bill did not do enough to protect victims of crime, saying, "This is not a criminal justice bill. It is a prisoner release bill. We should be protecting victims of crimes and not the offenders who committed the crimes." In 2023, he introduced a bill that would lower the amount of fentanyl a dealer must possess to face the mandatory minimum prison sentence. Kennedy has criticized prosecutors for declining to prosecute some offenders. In 2023, he introduced the Prosecutors Need to Prosecute Act, which requires prosecutors to disclose when they decline to prosecute cases. It would also remove funding for prosecutors who fail to report such cases.

December 7, 1995: Decree concerning the responsibilities of the Minister Delegate for Employment. June 6, 1996: Manifesto for gender parity published in L'Express; ten women, including former prominent ministers, are its authors. July 5, 1996: Law concerning adoption. January 14, 1997: Publication of selected excerpts from lawyer Gisèle Halimi's report to the Prime Minister on gender inequalities (social, economic, political), which undermine aspects of democracy; the report also proposes various solutions to reduce these inequalities and promote better democracy. June 11, 1997: Decree concerning the responsibilities of the Minister of Employment and Solidarity. December 19, 1997: Social Security Financing Law for 1998; it includes provisions relating to the family. March 8, 1998: Circular concerning the feminization of job titles, functions, ranks, or titles. March 16, 1998: Law concerning nationality. May 11, 1998: Law concerning the entry and residence of foreigners in France and the right of asylum. June 17, 1998: Constitutional bill for gender equality, including possibilities for measures promoting gender parity in political positions. June 17, 1998: Law concerning the prevention and repression of sexual offenses and the protection of minors. November 17, 1998: A State Secretariat for Women's Rights and Vocational Training is delegated to the Ministry of Employment and Solidarity. December 23, 1998: Social Security Financing Law for 1999, notably modifying certain elements relating to family allowances and the back-to-school allowance.

=== Historical evidence against balance of power theory === A 2021 assessment by Morten Skumsrud Andersen and William C. Wohlforth concluded that balance of power is not a universal empirical law and that it does not merit explanatory precedence in international relations research. In an attempt to disprove the balance of power theory, some realists have pointed to cases in international systems other than modern Europe where balancing failed and a hegemon arose. A collaboration between nine scholars (William Wohlforth, Richard Little, Stuart J. Kaufman, David Kang, Charles A. Jones, Victoria Tin-Bor Hui, Arthur Eckstein, Daniel Deudney, and William L. Brenner) pointed to the failure of state-like units to balance against Assyria in the first millennium BCE; the Hellenic successor states of Alexander the Great to balance against Rome; the Warring States to balance against the Qin dynasty in ancient China and five other cases. This cross-cultural research concludes:

Reactogenicity, the tendency of a vaccine to produce adverse reactions, is similar to that of conventional non-RNA vaccines. People susceptible to an autoimmune response may have an adverse reaction to messenger RNA vaccines. The advantages of mRNA vaccines over traditional vaccines are ease of design, speed and lower cost of production, the induction of both cellular and humoral immunity, and lack of interaction with the genomic DNA. While some messenger RNA vaccines, such as the Pfizer–BioNTech COVID-19 vaccine, have the disadvantage of requiring ultracold storage before distribution, other mRNA vaccines, such as the Moderna vaccine, do not have such requirements. In RNA therapeutics, messenger RNA vaccines have attracted considerable interest as COVID-19 vaccines. In December 2020, Pfizer–BioNTech and Moderna obtained authorization for their mRNA-based COVID-19 vaccines. On 2 December, the UK Medicines and Healthcare products Regulatory Agency (MHRA) became the first medicines regulator to approve an mRNA vaccine, authorizing the Pfizer–BioNTech vaccine for widespread use. In December 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization for the Pfizer–BioNTech vaccine and a week later similarly authorized the Moderna vaccine. In 2023 the Nobel Prize in Physiology or Medicine was awarded to Katalin Karikó and Drew Weissman for their discoveries concerning modified nucleosides that enabled the development of effective mRNA vaccines against COVID-19.

== Related compounds == A dual DOR and κ-opioid receptor (KOR) PAM, BMS-986187, derived from BMS-986122, has been developed and is selective for these receptors over the MOR. Another MOR PAM with a simpler synthesis, MS1, was subsequently developed and has shown similar effects to those of BMS-986122. Additionally, ignavine, a natural MOR PAM found in Aconitum, has also been identified. In 2024, ketamine and its metabolites norketamine and hydroxynorketamine (HNK) were identified as highly potent MOR, DOR, and KOR PAMs (active at a concentration of as low as 1 nM). These actions were implicated in their potential antidepressant and analgesic effects.

Sources: en.wikipedia.org

Notes from published material

== Medical training and career == Though born in Oklahoma City, Wilson grew up in Whittier, California. He completed his undergraduate degree in biology from California State University, Fullerton in 1974 and a master's degree in molecular biology and biochemistry from University of California, Irvine in 1977. He received his doctor of medicine degree from University of California, San Diego in 1984. The early part of his career saw him completing residency at the Mayo Clinic and taking professor and research roles at various universities. He served as a professor and Chair of the Department of Ophthalmology at the University of Washington in Seattle from 1998 to 2003, and was named Grace E. Hill Endowed Chair in Vision Research. Since 2003, he has been professor of ophthalmology and staff cornea and refractive surgeon at the Cleveland Clinic in Ohio, and he has served as the cornea and refractive fellowship director there 2006-2017. Wilson is the inventor of topical losartan treatment for corneal scarring/fibrosis. Wilson's laboratory studying corneal wound healing was funded by the National Eye Institute and the U.S. Department of Defense from 1993 to 2025.

Extraradical hyphae extend outward from the mantle into the soil, compensating for the suppression of root hairs by increasing the effective surface area of the colonized root. These hyphae can spread out singly, or in an aggregate arrangement known as a rhizomorph. These composite hyphal organs can have a wide range of structures. Some rhizomorphs are simply parallel, linear collections of hyphae. Others have more complex organization, for example the central hyphae may be larger in diameter than other hyphae, or the hyphae may grow continuously at the tip, penetrating into new areas in a way that superficially resembles meristematic activity. This part of the ectomycorrhiza, which is called the extraradical or extramatrical mycelium, functions largely as a transport structure. They often spread considerable distances, maintaining a large contact area with the soil. Some studies have shown a relationship between nutrient transport rates and the degree of rhizomorph organization. The rhizomorphs of different EcM types often have different organization types and exploration strategies, observed as different structure and growth within the soil. These differences also help identify the symbiotic fungus. The hyphae extending outward into the soil from an ectomycorrhiza can infect other nearby plants. Experiments and field studies show that this can lead to the formation of common mycorrhizal networks (CMNs) that allow sharing of carbon and nutrients among the connected host plants.

==== Violence ==== In 2018, a young woman was brutally attacked and left for dead by her ex-boyfriend. The victim, a university student, had ended the relationship, but the perpetrator couldn't accept it. He stalked her, attacked her with a machete, and left her with severe injuries. The case sparked outrage, highlighting the need to address gender-based violence and protect victims. In 2015, a violent incident occurred in Mzuzu, where a group of youths attacked a rival group, leaving several injured and one dead. The violence was sparked by a longstanding feud between the groups, highlighting the need for community interventions to address youth violence. In 2012, a shocking incident happened in Zomba, where a woman was attacked and burned alive by her husband. The perpetrator, a businessman, had a history of domestic violence. He doused his wife with petrol and set her alight, leaving her with severe burns. The case sparked widespread condemnation, highlighting the need for stronger laws to protect victims of domestic violence.

Libraries of peptide aptamers have been used as "mutagens", in studies in which an investigator introduces a library that expresses different peptide aptamers into a cell population, selects for a desired phenotype, and identifies those aptamers that cause the phenotype. The investigator then uses those aptamers as baits, for example in yeast two-hybrid screens to identify the cellular proteins targeted by those aptamers. Such experiments identify particular proteins bound by the aptamers, and protein interactions that the aptamers disrupt, to cause the phenotype. In addition, peptide aptamers derivatized with appropriate functional moieties can cause specific post-translational modification of their target proteins, or change the subcellular localization of the targets.

Sources: en.wikipedia.org

Frequently asked questions

What is epitalon made of?

It is a four-amino-acid peptide built from alanine, glutamate, aspartate and glycine in that order. Its formula is C14H22N4O9, and it is made by chemical synthesis rather than extracted from tissue. The synthetic peptide is a single defined molecule, unlike the pineal extracts it is often compared with.

Are epitalon and epithalon different compounds?

No. The two spellings refer to the same tetrapeptide, and the difference reflects transliteration from Russian. Laboratories and catalogues use both forms interchangeably. The material is also indexed as AEDG, taken from the one-letter codes of its residues.

How does epitalon differ from epithalamin?

Epithalamin is a mixed preparation derived from animal pineal tissue and contains many peptides. Epitalon is one synthetic sequence chosen for study from that broader mixture. Statements about one do not transfer directly to the other.

Which method confirms epitalon identity?

Mass spectrometry provides the identity check, because the observed mass is compared with the theoretical mass of the AEDG sequence. Chromatography separates and quantifies impurities but does not by itself prove which peptide is present. The two techniques are normally used together.

Network